Biotech Values

[topicviewer]

FYI: BIIB & PDLI = They finally figured out that mono is what you do with MS

DJ Biogen, PDL:Primary Endpoint Met In Phase II Daclizumab Trial

DOW JONES NEWSWIRES

Biogen Idec Inc. (BIIB) and PDL BioPharma Inc.(PDLI) said the ongoing Phase II trial of daclizumab met its primary endpoint in relapsing multiple sclerosis patients being treated with interferon beta.

Patients receiving daclizumab 2 milligrams/kg subcutaneously every two weeks showed a "significant reduction" in the number of new or enlarged gadolinium-contrast-enhancing lesions at week 24, the companies said Monday.

The companies plan to begin a Phase II monotherapy trial of daclizumab, and to advance the overall clinical development program in relapsing MS.

Patients in the CHOICE trial were randomized to receive daclizumab 2 mg/kg every two weeks, daclizumab 1 mg/kg every four weeks or placebo added to ongoing interferon beta treatment.
Patients are being followed for another 48 weeks after the daclizumab treatment period to further assess safety and efficacy.

-Jenny Park; 201-938-5400; [e-mail]

(END) Dow Jones Newswires